Pharmaceutical Composition for Improving and Treating Leukotrichia and/or Alopecia and Preparation Method Thereof
US-2024325505-A1 · Oct 3, 2024 · US
Method for blocking HIV entry into dendritic cells by inhibiting sialoadhesin-sialyllactose binding interactions with gangliosides
US9789130B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9789130-B2 |
| Application number | US-201214366839-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 17, 2012 |
| Priority date | Dec 22, 2011 |
| Publication date | Oct 17, 2017 |
| Grant date | Oct 17, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for blocking the entry of HIV into dendritic cells in a subject in need thereof, said method comprising administering to said subject an inhibitor of the interaction between sialoadhesin and sialyllactose, wherein said inhibitor is a vesicle comprising a molecule comprising a sialyllactose moiety, and wherein said molecule is a ganglioside having less than four sialic acids. 2. The method according to claim 1 , wherein the HIV is HIV-1.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9789130B2 cover?
- The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest wher…
- Who is the assignee on this patent?
- Izquierdo Useros Nuria, Krauesslich Hans-Georg, Lorizate Maier, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7028. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).